




Instance: composition-en-b1fb2a2948a2c3c9fab67f4b0e8ec1e3
InstanceOf: CompositionUvEpi
Title: "Composition for mozobil Package Leaflet"
Description:  "Composition for mozobil Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8fb12324a4d0b40e6ba6451527e4626c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - mozobil"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Mozobil is and what it is used for </li>
<li>What you need to know before you use Mozobil </li>
<li>How to use Mozobil </li>
<li>Possible side effects </li>
<li>How to store Mozobil </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What mozobil is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What mozobil is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Mozobil contains the active substance plerixafor which blocks a protein on the surface of blood stem 
cells. This protein  ties  blood stem cells to the bone marrow. Plerixafor improves the release of stem 
cells into the blood stream (mobilisation). The stem cells can then be collected by a machine that 
separates blood constituents (apheresis machine), and subsequently frozen and stored until your 
transplant. </p>
<p>If mobilisation is poor, Mozobil is used to help collect blood stem cells from the patient, for collection, 
storage and reintroduction (transplantation), 
* In adults who have lymphoma (a cancer of the white blood cells) or multiple myeloma (a cancer 
that affects plasma cells in the bone marrow). 
* In children age 1 to less than 18 years of age with lymphoma or solid tumours.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take mozobil"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take mozobil"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Mozobil<br />
* if you are allergic to plerixafor or any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>Warnings and precautions<br />
Talk to your doctor before using Mozobil.  </p>
<p>Tell your doctor:<br />
<em> if you have or have had any heart problems. 
* if you have kidney problems. Your doctor may adjust the dose. 
* if you have high white blood cell counts.<br />
</em> if you have low platelet counts. 
* if you have a history of feeling faint or lightheaded on standing or sitting or have fainted before 
upon injections. </p>
<p>Your doctor may perform regular blood tests to monitor your blood cell count. </p>
<p>It is not recommended to use Mozobil for stem cell mobilisation if you have leukaemia (a cancer of 
the blood or bone marrow). </p>
<p>Other medicines and Mozobil 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Pregnancy and breast-feeding<br />
You should not use Mozobil if you are pregnant, since there is no experience with Mozobil in pregnant 
women. It is important to tell your doctor if you are, think you may be or are planning to become 
pregnant. It is recommended to use contraception if you are of child-bearing age.  </p>
<p>You should not breast-feed if you are using Mozobil, since it is not known if Mozobil is excreted in 
human milk.  </p>
<p>Driving and using machines 
Mozobil may cause dizziness and fatigue. Therefore, you should avoid driving if you feel dizzy, tired 
or unwell. </p>
<p>Mozobil contains sodium<br />
This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take mozobil"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take mozobil"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your medicine will be injected by a doctor or a nurse.  </p>
<p>You will first receive G-CSF, then you will be given Mozobil 
Mobilisation will be started by first giving you another medicine called G-CSF (granulocyte-colony 
stimulating factor). G-CSF will help Mozobil to work properly in your body. If you want to know 
more about G-CSF ask your doctor and read the corresponding package leaflet. </p>
<p>How much Mozobil is given? 
The recommended adult dose is either a 20 mg (fixed dose) or 0.24 mg/kg body weight/day.<br />
The recommended dose for children, 1 to less than 18 years of age is 0.24 mg/kg of body weight/day.  </p>
<p>Your dose will depend on your body weight, which should be measured the week before you receive 
your first dose. If you have moderate or severe kidney problems, your doctor will reduce the dose.  </p>
<p>How is Mozobil given? 
Mozobil is given by subcutaneous injection (under your skin). </p>
<p>When is Mozobil given for the first time? 
You will receive your first dose 6 to 11 hours before apheresis (collection of your blood stem cells). </p>
<p>How long will Mozobil be given? 
Treatment lasts 2 to 4 consecutive days (in some cases up to 7 days), until enough stem cells have 
been collected for your transplant. In a few cases, enough stem cells may not be collected, and the 
collection attempt will be stopped. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Please tell your doctor immediately if<br />
* shortly after receiving Mozobil, you experience rash, swelling around the eyes, shortness of 
breath or lack of oxygen, feeling lightheaded on standing or sitting, feeling faint or fainting 
* you have pain in the upper left abdomen (belly) or your left shoulder </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
* diarrhoea, nausea (feeling sick), injection site redness or irritation 
* low red blood cell count by laboratory test (anaemia in children) </p>
<p>Common side effects (may affect up to 1 in 10 people) 
* headache<br />
<em> dizziness, feeling tired or unwell<br />
</em> difficulty in sleeping 
* flatulence, constipation, indigestion, vomiting<br />
<em> stomach symptoms such as pain, swelling or discomfort<br />
</em> dry mouth, numbness around the mouth<br />
* sweating, generalised redness of the skin, joint pains, pains in muscles and bones </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
* allergic reactions such as skin rash, swelling around the eyes, shortness of breath 
* anaphylactic reactions, including anaphylactic shock 
* abnormal dreams, nightmares </p>
<p>Rarely, gastrointestinal side effects may be severe (diarrhoea, vomiting, stomach pain and nausea). </p>
<p>Heart attacks 
In clinical trials, patients with risk factors for a heart attack uncommonly suffered heart attacks after 
being given Mozobil and G-CSF. Please inform your doctor immediately if you experience chest 
discomfort. </p>
<p>Pins and needles and numbness 
Pins and needles and numbness are common in patients being treated for cancers. About one in five 
patients suffered from these feelings. However, these effects do not seem to occur more frequently 
when you use Mozobil. 
You may also have an increase in white blood cells count (leucocytosis), in your blood tests. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store mozobil"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store mozobil"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and vial. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>After opening the vial, Mozobil should be used immediately. </p>
<p>Do not throw away any medicines via wastewater or household waste. The pharmacist will throw 
away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Mozobil contains 
- The active substance is plerixafor. Each ml solution for injection contains 20 mg plerixafor. Each 
vial contains 24 mg plerixafor in 1.2 ml solution. 
- The other ingredients are sodium chloride, hydrochloric acid (concentrated) and sodium hydroxide 
for pH adjustment and water for injections. </p>
<p>What Mozobil looks like and contents of the pack 
Mozobil is supplied as a clear colourless or pale yellow solution for injection in a glass vial with a 
non-latex rubber stopper. Each vial contains 1.2 ml solution. </p>
<p>Each pack contains 1 vial. </p>
<p>Marketing Authorisation Holder 
Sanofi B.V. 
Paasheuvelweg 1105 BP Amsterdam 
The Netherlands. </p>
<p>Manufacturer 
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien/ 
Luxembourg/Luxemburg 
Sanofi Belgium 
T l/Tel: + 32 2 710 54 Lietuva 
Swixx Biopharma UAB 
Tel. +370 5 236 91 <br />
Swixx Biopharma EOOD 
T : +359 (0)2 4942 Magyarorsz g 
SANOFI-AVENTIS Zrt. 
Tel: +36 1 505 0 esk  republika 
Sanofi s.r.o. 
Tel: +420 233 086 Malta 
Sanofi S.r.l. 
Tel: +39 02 39394Danmark 
sanofi A/S<br />
Tlf: +45 45 16 70 Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel:  0800 52 52 Tel. aus dem Ausland: +49 69 305 21 Norge 
sanofi-aventis Norge AS 
Tlf: + 47 67 10 71 Eesti 
Swixx Biopharma O<br />
Tel. +372 640 10  sterreich 
sanofi-aventis GmbH 
Tel: + 43 1 80 185 - 0 </p>
<p>Sanofi-Aventis   AEBE<br />
 : +30 210 900 1Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00 Espa a 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 Portugal 
Sanofi   Produtos Farmac uticos, Lda. 
Tel: +351 21 35 89 France 
Sanofi Winthrop Industrie 
T l : 0 800 222 Appel depuis l tranger : +33 1 57 63 23 Rom nia 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078 Slovenija 
Swixx Biopharma d.o.o. 
Tel: +386 1 235 51 Ireland 
sanofi-aventis Ireland Ltd T/A SANOFI 
Tel:  +353 (0) 1 4035 Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel.:  +421 2 208 33  sland 
Vistor hf. 
S mi: +354 535 7Suomi/Finland 
Sanofi Oy 
Puh/Tel: + 358 201 200 Italia 
Sanofi S.r.l. 
Tel: 800536Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50 Latvija 
Swixx Biopharma SIA 
Tel: +371 6 616 47 <br />
C.A. Papaellinas Ltd. 
 : +357 22 741United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2This leaflet was last approved in.  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-b1fb2a2948a2c3c9fab67f4b0e8ec1e3
InstanceOf: CompositionUvEpi
Title: "Composition for mozobil Package Leaflet"
Description:  "Composition for mozobil Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8fb12324a4d0b40e6ba6451527e4626c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - mozobil"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at bruge Mozobil 
3. Sådan skal du bruge Mozobil 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What mozobil is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What mozobil is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Mozobil indeholder det aktive stof plerixafor, der blokerer for et protein på overfladen af 
blodstamceller. Dette protein binder blodstamcellerne til knoglemarven. Plerixafor forbedrer 
frigivelsen af stamceller ud i blodbanen (mobilisering). Stamcellerne kan indsamles ved hjælp af en 
maskine, der adskiller blodets indholdsstoffer (aferese-maskine), og derefter nedfryses og opbevares 
indtil transplantationen. </p>
<p>Hvis det er vanskeligt at mobilisere, anvendes Mozobil til at hjælpe med at opsamle blodstamceller fra 
patienten med henblik på indsamling, opbevaring og genindførelse (transplantation),  </p>
<ul>
<li>
<p>Hos voksne, der har lymfom (kræft i de hvide blodlegemer) eller multipelt myelom (en 
kræftform, som påvirker plasmacellerne i knoglemarven). </p>
</li>
<li>
<p>Hos børn i alderen 1 - under 18 år, der har lymfom eller solide tumorer (tumor der udgår fra de 
solide organer som f.eks. lunger, mave-tarm, hoved-hals, lever osv.). </p>
</li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take mozobil"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take mozobil"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Mozobil </p>
<ul>
<li>hvis du er allergisk over for plerixafor eller et af de øvrige indholdsstoffer i Mozobil (angivet i 
punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du bruger Mozobil. </p>
<p>Kontakt lægen:  </p>
<ul>
<li>
<p>hvis du har eller har haft hjerteproblemer. </p>
</li>
<li>
<p>hvis du har nyreproblemer. Lægen vil muligvis justere din dosis. </p>
</li>
<li>
<p>hvis du har et højt antal hvide blodlegemer.  </p>
</li>
<li>
<p>hvis du har et lavt antal blodplader. </p>
</li>
<li>
<p>hvis du tidligere har haft en følelse af at skulle besvime, eller du er blevet svimmel, når du rejser 
eller sætter dig op, eller du er besvimet i forbindelse med en injektion. </p>
</li>
</ul>
<p>Din læge vil muligvis tage regelmæssige blodprøver for at kontrollere dit blodcelletal. </p>
<p>Det frarådes at bruge Mozobil, hvis du har leukæmi (kræft i blodet eller knoglemarven). </p>
<p>Brug af anden medicin sammen med Mozobil 
Fortæl altid lægen eller på apoteket, hvis du bruger anden medicin eller har gjort det for nylig. Dette 
gælder også medicin, som ikke er købt på recept f.eks. naturlægemidler og vitaminer og mineraler. </p>
<p>Graviditet og amning<br />
Du må ikke bruge Mozobil, hvis du er gravid, da der ikke er nogen erfaring med anvendelse af 
Mozobil til gravide. Det er vigtigt, at du fortæller det til lægen, hvis du er gravid, kan være gravid, 
eller planlægger at blive gravid. Det anbefales at anvende prævention, hvis du er i den fødedygtige 
alder. </p>
<p>Du bør ikke amme, hvis du bruger Mozobil, da det ikke vides, om Mozobil udskilles i modermælken.  </p>
<p>Trafik- og arbejdssikkerhed 
Mozobil kan forårsage svimmelhed og træthed. Kør derfor ikke, hvis du føler dig svimmel, træt eller 
utilpas. </p>
<p>Natrium 
Denne medicin indeholder mindre end 1 mmol (23 mg) natrium pr. Dosis, dvs. Den er i det væsentlige 
natriumfri.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take mozobil"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take mozobil"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Din medicin vil blive injiceret af en læge eller sygeplejerske.  </p>
<p>Du begynder med at få G-CSF og derefter Mozobil 
Behandlingen begynder med, at du først får et andet lægemiddel, der kaldes for G-CSF 
(granulocytkoloni-stimulerende faktor). G-CSF hjælper Mozobil med at virke rigtigt i din krop. Spørg 
lægen og læs den medfølgende indlægsseddel, hvis du vil vide mere om G-CSF. </p>
<p>Hvor meget Mozobil skal du have? 
Den anbefalede dosis til voksne er enten en 20 mg (fast dosis) eller 0,24 mg pr.kg legemsvægt pr. Dag.<br />
Den anbefalede dosis til børn i alderen 1 - under 18 år er 0,24 mg pr.kg legemsvægt pr. Dag. </p>
<p>Din dosis afhænger af din legemsvægt, som skal måles, i ugen før du får din første dosis. Din læge vil 
reducere dosis, hvis du har moderate eller svære nyreproblemer.  </p>
<p>Hvordan gives Mozobil? 
Mozobil gives med en injektion under huden (subkutan injektion). </p>
<p>Hvornår gives Mozobil første gang? 
Du får din første dosis 6 til 11 timer inden opsamling af dine blodstamceller (aferesen). </p>
<p>Hvor lang tid gives Mozobil? 
Behandlingen varer 2 til 4 dage i træk (i nogle tilfælde i op til 7 dage), indtil der er indsamlet nok 
stamceller til din transplantation. I nogle få tilfælde kan der muligvis ikke indsamles nok stamceller, 
og forsøget på at indsamle dem vil blive afbrudt. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Fortæl det straks til lægen, hvis </p>
<ul>
<li>
<p>du kort tid efter at have fået Mozobil får udslæt, hævelse omkring øjnene, stakåndethed eller 
åndenød, eller du føler dig ør, når du står op eller sidder ned, eller føler, at du skal besvime, eller 
du besvimer. </p>
</li>
<li>
<p>du får smerter i øverste venstre del af maven eller i din venstre skulder. </p>
</li>
</ul>
<p>Meget almindelige bivirkninger (kan påvirke flere end 1 ud af 10 personer) </p>
<ul>
<li>
<p>diaré, kvalme, rødmen eller irritation på injektionsstedet </p>
</li>
<li>
<p>lavt antal røde blodlegemer påvist i laboratorieprøve (anæmi hos børn) </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan påvirke op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>hovedpine  </p>
</li>
<li>
<p>svimmelhed, træthed eller utilpashed  </p>
</li>
<li>
<p>søvnbesvær </p>
</li>
<li>
<p>luft i maven, forstoppelse, fordøjelsesbesvær, opkastning  </p>
</li>
<li>
<p>symptomer i maven såsom smerter, hævelse eller ubehag  </p>
</li>
<li>
<p>mundtørhed, følelsesløshed omkring munden  </p>
</li>
<li>
<p>øget svedtendens, generel rødme i huden, ledsmerter, smerter i muskler og knogler </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan påvirke op til 1 ud af 100 personer) </p>
<ul>
<li>
<p>allergiske reaktioner såsom udslæt i huden, hævelse omkring øjnene, stakåndethed </p>
</li>
<li>
<p>anafylaktiske reaktioner, herunder anafylaktisk shock </p>
</li>
<li>
<p>unormale drømme, mareridt </p>
</li>
</ul>
<p>Bivirkninger i mave-tarm-kanalen kan i sjældne tilfælde være kraftige (diaré, opkastning, mavepine og 
kvalme). </p>
<p>Hjerteanfald 
I kliniske studier fik patienter med risiko for hjerteanfald, i sjældne tilfælde et hjerteanfald efter at 
have fået Mozobil og G-CSF. Kontakt straks lægen, hvis du mærker ubehag i brystet. </p>
<p>Snurren og prikken og følelsesløshed 
Snurren og prikken og følelsesløshed er almindeligt hos patienter, der behandles for kræft. Cirka én ud 
af fem patienter får disse bivirkninger. Brugen af Mozobil synes dog ikke at påvirke denne hyppighed. </p>
<p>Du kan også have et øget antal hvide blodlegemer (leukocytose) i dine blodprøver. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store mozobil"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store mozobil"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn. </p>
<p>Brug ikke dette lægemiddel efter den udløbsdato, der står på kartonen og hætteglasset. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Mozobil skal anvendes med det samme, når hætteglasset er åbnet. </p>
<p>Apoteket vil bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide medicinrester i afløbet, 
toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Mozobil indeholder:</p>
<ul>
<li>Aktivt stof: plerixafor. Hver ml injektionsvæske, opløsning indeholder 20 mg plerixafor. Hvert 
hætteglas indeholder 24 mg plerixafor i 1,2 ml opløsning. </li>
<li>Øvrige indholdsstoffer: natriumchlorid, saltsyre og natriumhydroxid til pH-justering, vand til 
injektionsvæsker. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Mozobil leveres som en gennemsigtig, farveløs eller lysegul injektionsvæske, opløsning, i et hætteglas 
med en latexfri gummiprop. Hvert hætteglas indeholder 1,2 ml opløsning. </p>
<p>Hver pakning indeholder 1 hætteglas. </p>
<p>Indehaver af markedsføringstilladelsen 
Sanofi B.V. 
Paasheuvelweg 1105 BP Amsterdam 
Holland </p>
<p>Fremstiller 
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien/ 
Luxembourg/Luxemburg 
Sanofi Belgium 
Tél/Tel: + 32 2 710 54<br />
Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91<br />
България 
Swixx Biopharma EOOD 
Тел.: +359 (0)2 4942<br />
Magyarország 
SANOFI-AVENTIS Zrt. 
Tel: +36 1 505 0Česká republika 
Sanofi s.r.o. 
Tel: +420 233 086<br />
Malta 
Sanofi S.r.l. 
Tel: +39 02 39394 
Danmark 
Sanofi A/S 
Tlf: +45 45 16 70<br />
Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21<br />
Norge 
sanofi-aventis Norge AS 
Tlf: + 47 67 10 71<br />
Eesti 
Swixx Biopharma OÜ<br />
Tel: +372 640 10 <br />
Österreich 
sanofi-aventis GmbH 
Tel: + 43 1 80 185 - 0 
Ελλάδα 
Polska 
Sanofi-Aventis Μονοπρόσωπη AEBE<br />
Τηλ: +30 210 900 1sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00<br />
España 
sanofi-aventis, S.A. 
Tel: +34 93 485 94<br />
Portugal 
Sanofi - Produtos Farmacêuticos, Lda. 
Tel: +351 21 35 89<br />
France 
Sanofi Winthrop Industrie 
Tél : 0 800 222 Appel depuis l’étranger : +33 1 57 63 23<br />
România 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 36<br />
Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078<br />
Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 235 51<br />
Ireland 
sanofi-aventis Ireland Ltd T/A SANOFI 
Tel:  +353 (0) 1 4035 600  </p>
<p>Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33 <br />
Ísland 
Vistor hf. 
Sími: +354 535 7Suomi/Finland 
Sanofi Oy 
Puh/Tel: + 358 201 200<br />
Italia 
Sanofi S.r.l. 
Tel: 800536 
Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50<br />
Latvija<br />
Swixx Biopharma SIA<br />
Tel: +371 6 616 47<br />
United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2 
Κύπρος 
C.A. Papaellinas Ltd. 
Τηλ: +357 22 741 </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-b1fb2a2948a2c3c9fab67f4b0e8ec1e3
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for mozobil Package Leaflet for language en"
Description: "ePI document Bundle for mozobil Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-b1fb2a2948a2c3c9fab67f4b0e8ec1e3"
* entry[0].resource = composition-en-b1fb2a2948a2c3c9fab67f4b0e8ec1e3

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb1fb2a2948a2c3c9fab67f4b0e8ec1e3"
* entry[=].resource = mpb1fb2a2948a2c3c9fab67f4b0e8ec1e3
                            
                    
Instance: bundlepackageleaflet-da-b1fb2a2948a2c3c9fab67f4b0e8ec1e3
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for mozobil Package Leaflet for language da"
Description: "ePI document Bundle for mozobil Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-b1fb2a2948a2c3c9fab67f4b0e8ec1e3"
* entry[0].resource = composition-da-b1fb2a2948a2c3c9fab67f4b0e8ec1e3

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb1fb2a2948a2c3c9fab67f4b0e8ec1e3"
* entry[=].resource = mpb1fb2a2948a2c3c9fab67f4b0e8ec1e3
                            
                    



Instance: mpb1fb2a2948a2c3c9fab67f4b0e8ec1e3
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product mozobil"
Description: "mozobil"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/09/537/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Adult patients"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "mozobil"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: b1fb2a2948a2c3c9fab67f4b0e8ec1e3ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "mozobil"

* status = #current
* mode = #working

* title = "List of all ePIs associated with mozobil"

* subject = Reference(mp8fb12324a4d0b40e6ba6451527e4626c)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#mozobil "mozobil"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-b1fb2a2948a2c3c9fab67f4b0e8ec1e3) // mozobil en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-b1fb2a2948a2c3c9fab67f4b0e8ec1e3) // mozobil da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-b1fb2a2948a2c3c9fab67f4b0e8ec1e3
InstanceOf: List

* insert b1fb2a2948a2c3c9fab67f4b0e8ec1e3ListRuleset
    